Previous 10 | Next 10 |
2023-07-12 08:24:50 ET Ault Alliance ( NYSE: AULT ) +152% . Healthcare Triangle ( HCTI ) +127% . Cadrenal Therapeutics ( CVKD ) +61% . Liminal BioSciences ( LMNL ) +40% to go private in buyout deal with Structured Alpha. BitNil...
2023-06-22 06:40:45 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips With patent expirations around the corner, some of the biggest pharmaceutical and biotech companies will soon face generic competition, creating a big opportunity for these top biotech stocks...
BOSTON, June 14, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that ...
BOSTON, June 07, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that ...
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that ...
2023-05-26 06:19:56 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Now is a great time to start accumulating top biotech stocks . The biotech boom is red-hot. And there are no signs of it cooling off. After all, we can’t stop people from aging &...
As of the data cutoff date, nine of the 14 evaluable patients treated with CUE-101+ KEYTRUDA® (pembrolizumab) demonstrated tumor regression, with five confirmed partial responses (PRs) and three durable stable disease (DSD) responses, two of which have tumor burden reductions of -18% and -24...
2023-05-19 15:00:19 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week, or the Seeking Alpha earnings calendar ...
Company to host Investor Update call on June 14, 2023 to review and discuss the clinical progress and associated data presented at ASCO BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class...
2023-05-09 18:01:56 ET Cue Biopharma press release ( NASDAQ: CUE ): Q1 GAAP EPS of -$0.29 in-line. Revenue of $0.19M (-81.0% Y/Y) misses by $1.76M . For further details see: Cue Biopharma GAAP EPS of -$0.29 in-line, revenue of $0.19M misses by $1.76M
News, Short Squeeze, Breakout and More Instantly...
Prioritizing autoimmune programs aims to focus upon near-term and intermediate value creation potential, while retaining oncology programs as promising clinical data continues to mature - Company anticipates annualized capital and workforce requirements to be reduced by approximately 25...
Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+ head and neck squamous cell carcinoma (HNSCC) treated with CUE-101 and KEYTRUDA ® (pembrolizumab) Median overall survival (mOS) of 20.8 months in second...
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced that it will participate in two investor confe...